This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MORRIS PLAINS, N.J., May 7, 2013 (GLOBE NEWSWIRE) --
Immunomedics, Inc. (Nasdaq:IMMU)
, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has received notice that its patent application for "Delivery system for cytotoxic drugs by bispecific antibody pretargeting," will issue as US patent No. 8,435,539 today.
This patent relates to compositions for pretargeting delivery of therapeutic agents for use with bispecific antibodies generated by the Company's proprietary DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The allowed claims under the patent cover the use of conjugates of therapeutic agents, such as SN-38, for cancer or other diseases, until the year 2026.
SN-38 is the active form of, and about three orders of magnitude more potent than, irinotecan or CPT-11,an FDA-approved drug for metastatic colorectal cancer treatment. The powerful cancer drug cannot be administered systemically to patients because of its toxicity and poor solubility in water. We have conjugated SN-38 to two of our humanized antibodies, labetuzumab and hRS7, for targeted delivery to cancer cells. The two antibody-drug conjugates are being evaluated in separate Phase I trials for solid cancer therapy.
The Company has also received notice that its patent application for "Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy," will issue as US patent No. 8,435,529 today. The new patent covers the use of clivatuzumab and hRS7, and fragments thereof, for the treatment of pancreatic cancer and other forms of cancer. The allowed claims protect the use of yttrium-90-labeled clivatuzumab, which is being developed for the treatment of patients with advanced or metastatic pancreatic cancer, and hRS7-SN-38 until 2023.
In addition, IBC Pharmaceuticals, Inc., the Company's majority-owned subsidiary, has received notice that additional claims for the patent family,"Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo," will issue as U.S. patent no. 8,435,540 today.